Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving ≥2000 mg Daily Dose of Levodopa.

Conclusions: Patients who require ≥2000 mg/day LCIG exhibited a safety profile comparable to the established safety/tolerability of LCIG with similar clinical improvements. Higher AEs were noted but within what is accepted for LCIG. Continuous administration of LCIG is beneficial to advanced PD patients who require very high doses of levodopa. PMID: 32104560 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/32104560?dopt=Abstract

Source: Parkinsons Disease - February 28, 2020 Category: Neurology Tags: Parkinsons Dis Source Type: research

More News: Carbidopa/Levodopa | Neurology | Parkinson's Disease | Study